Drug Trial Radar · NCT00931736
Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness
Last checked: Nov 19, 2026Latest source record: Dec 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,031
Actual
Start
Aug 2009
Primary completion
Apr 2017
Study completion Apr 2017
Sponsor
- Lead sponsor
- McGill UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- First posted
- Jul 2, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
On a global scale, tuberculosis (TB) is the single most important infectious cause of morbidity and mortality. The World Health Organization has estimated that one-third of the entire world's population carries latent TB infection. A key TB control strategy is therapy of latent TB infection (LTBI). The current standard regimen is 9 months of Isoniazid (9INH). This regimen has excellent efficacy if taken regularly, but its effectiveness is substantially reduced by poor compliance. Serious side effects, such as hepato-toxicity can occur. Three shorter alternatives have been recommended: 6 months INH (6INH), 2 months Rifampin - Pyrazinamide (2RIF-PZA) and 4 months Rifampin (4RIF). The regimen of 6INH is less efficacious than 9INH, while 2RIF-PZA has been largely abandoned because of serious toxicity. Based on some evidence in treatment of LTBI, and extrapolating from extensive experience with treatment of active TB, it is believed that 4RIF has similar efficacy as 9INH. Therefore, the investigators are initiating the first multi-site international randomized trial that will compare the effectiveness of 4RIF and 9INH in preventing active tuberculosis.
Conditions
- Latent Tuberculosis Infection
Interventions
IsoniazidDrug
The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
RifampinDrug
The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed active TB during 28 months after randomizationTime frame: 7 years total with data analysis
Locations
12 sites in 9 countries. Site status is shown where the registry gives one.
Woolcock Institute of Medical Research
Sydney, New South Wales, Australia
Centre de Pneumophthysiologie
Cotonou, Benin
Universidade Gama Filho, Centro de Ciências Biológicas e da Saúde
Rio de Janeiro, Brazil
University of Alberta
Edmonton, Alberta, Canada
British Columbia Centre for Disease Control
Vancouver, British Columbia, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
Royal University Hospital
Saskatoon, Saskatchewan, Canada
Research and Development Unit, Komfo Anokye Teaching Hospital
Kumasi, Ghana
Service de Phtisiologie, Hopital National Ignace Deen
Conakry, Guinea
Health Research Unit, Faculty of Medicine
Bandung, West Java, Indonesia
King Fahad National Guard Hospital
Riyadh, Saudi Arabia
Korean Institute of Tuberculosis
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.